Mary L. Gemignani

The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable With That of Axillary Lymph Node Dissection

Arpana Naik, Jane V. Fey, Mary L. Gemignani et al. · Annals of Surgery · 2004 · 400 citations · Full text

Medicine, Surgery, Breast Oncology +16

How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

Anita Mamtani, Andrea V. Barrio, Tari A. King et al. · Annals of Surgical Oncology · 2016 · 309 citations

Medicine, Oncology, Surgery +16

Sentinel lymph node mapping for grade 1 endometrial cancer: Is it the answer to the surgical staging dilemma?

Nadeem R. Abu‐Rustum, Fady Khoury‐Collado, Neeta Pandit‐Taskar et al. · Gynecologic Oncology · 2009 · 218 citations · Full text

Medicine, Oncology, Surgery +17

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma

Mary L. Gemignani, Alan C. Schlaerth, Faina Bogomolniy et al. · Gynecologic Oncology · 2003 · 213 citations

Medicine, Molecular Genetics, Oncology +14

Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer

Leslie L. Montgomery, Alisa C. Thorne, Kimberly J. Van Zee et al. · Anesthesia & Analgesia · 2002 · 207 citations

Medicine, Oncology, Allergy +16